<DOC>
	<DOCNO>NCT00803816</DOCNO>
	<brief_summary>Study efficacy everolimus course uveitis : - obtain quiescence inflammation start treatment - duration obtain quiescence inflammation - number patient quiescence inflammation</brief_summary>
	<brief_title>Everolimus Treatment Uveitis Unresponsive Cyclosporine A</brief_title>
	<detailed_description>occurence new complication uveitis - course visual acuity ( LogMAR ) : percentage patient visual loss 10 number ETDRS compare baseline - change recurrence rate compare time everolimus treatment - occurence recurrence obtain remission everolimus treatment - duration occurence recurrence number patient recurrence - corticosparing effect everolimus - number patient without topical corticosteroid ; number patient reduce topical corticosteroid ( &lt; 3x/daily ) - number patient without systemic corticosteroid ; number patient reduce systemic corticosteroid ( &lt; 10mg/daily ) - efficacy uveitis within 12 month - maintenance remission withdrawel everolimus treatment 12 month course cystoid macula edema ( FLA , OCT )</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>endogenous intermediate posterior uveitis quiesence previous 3 month systemic topical steroid systemic cyclosporine A indication steroid spar therapy uveitis relate vision threating complication negative pregnancy test effective contraception Ophthalmic parameter : silicone oil anterior chamber eye para intraocular corticosteroid injection within previous 8 week opacities optic medium obscure visualization anterior posterior eye segment General parameter : requirement combine immunosuppression systemic immunemediated disease contraindication everolimus cyclosporine A positive tuberculine test ( GT 10 currently immunosuppressive therapy immunosuppressive drug cyclosporine poor compliance know intolerance medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>endogoneous</keyword>
	<keyword>posterior</keyword>
	<keyword>intermediate</keyword>
</DOC>